DTDavid Tordrup

David Tordrup

*This is an algorithmically generated author record based on publicly available information.

David Tordrup has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A systematic review of policies regulating or removing mark-ups in the pharmaceutical supply and distribution chain

    by Iris R. Joosse, David Tordrup, Julie Glanville, Aukje K. Mantel-Teeuwisse, Hendrika A. van Den Ham


  • Open Access

    Evidence on the effectiveness of policies promoting price transparency - A systematic review

    by Iris R. Joosse, David Tordrup, Julie Glanville, Eleanor Kotas, Aukje K. Mantel-Teeuwisse, Hendrika A. van Den Ham


  • Open Access

    A critical review of methodologies used in pharmaceutical pricing policy analyses

    by Iris R. Joosse, David Tordrup, Lisa Bero, Aukje K. Mantel-Teeuwisse, Hendrika A. van Den Ham


  • Open Access

    Economic burden of female genital mutilation in 27 high-prevalence countries

    by David Tordrup, Chrissy Bishop, Nathan Green, Max Petzold, Fernando Ruiz Vallejo, Joshua P Vogel, Christina Pallitto

    Background Female genital mutilation (FGM) is a traditional harmful practice affecting 200 million women and girls globally. Health complications of FGM occur immediately and over time, and are associated with healthcare costs that are poorly understood. Quantifying the global FGM-related burden is essential for supporting programmes and policies for prevention and mitigation. Methods Health complications of FGM are derived from a meta-analysis and stratified by acute, uro-gynaecological, obstetric and psychological/sexual. Treatment costs are calculated from national cohort models of 27 high-burden countries over 30 years. Savings associated with full/partial abandonment are compared with a current incidence reference scenario, assuming no changes in FGM practices. Results Our model projects an increasing burden of FGM due to population growth. As a reference scenario assuming no change in practices, prevalent cases in 27 countries will rise from 119.4 million (2018) to 205.8 million (2047). Full abandonment could reduce this to 80.0 million (2047), while partial abandonment is insufficient to reduce cases. Current incidence economic burden is US$1.4 billion/year, rising to US$2.1 billion/year in 2047. Full abandonment would reduce the future burden to US$0.8 billion/year by 2047. Conclusion FGM is a human rights violation, a public health issue and a substantial economic burden that can be avoided through effective prevention strategies. While decreasing trends are observed in some countries, these trends are variable and not consistently observed across settings. Additional resources are needed to prevent FGM to avoid human suffering and growing costs. The findings of this study warrant increased political commitment and investment in the abandonment of FGM.


  • Open Access

    Public-private partnerships and collaboration in digital health: a scoping review and case study analysis of applications during the COVID-19 pandemic (Preprint)

    by Nishali Kirit Patel, Elinor Wahal, Adriana Mancilla Galindo, Alejandra Rodarte, Tim Jesudason, Rebekka Aarsand, David Tordrup

    BACKGROUND The emergence of digital technologies over the past decade has presented a novel opportunity to address healthcare challenges associated with COVID-19 and accelerate progress towards achieving the health-related goals under the 2030 Sustainable Development Agenda. Public-private partnerships (PPPs) have played a vital role in scaling up digital health solutions and disseminating curated scientific information in the face of the infodemic. However, several challenges remain around the effectiveness of PPP-related digital solutions and antagonistic viewpoints of engaging the private sector. We sought to evaluate the role of public-private partnerships in the digital public health space during COVID-19 and identify key lessons learned and challenges in the uptake of digital health solutions globally. OBJECTIVE Electronic and grey literature search results from PubMed, Google, and Google Scholar were screened by one reviewer through a two-stage process. We included all relevant systematic reviews, interventional, observational, and descriptive studies published in English published from January 2020 to June 2021. Two case study analyses on digital health chatbots, informed by expert opinion, were also performed to assess for the role of public-private partnerships in advancing digital public health solutions. METHODS Electronic and grey literature search results from PubMed, Google, and Google Scholar were screened by one reviewer through a two-stage process. We included all relevant systematic reviews, interventional, observational, and descriptive studies published in English published from January 2020 to June 2021. Two case study analyses on digital health chatbots, informed by expert opinion, were also performed to assess for the role of public-private partnerships in advancing digital public health solutions. RESULTS Forty-five articles met the inclusion criteria for qualitative analysis, the majority of which were secondary research. Results of the publications can be broadly categorized into three groups: (1) models and definitions of public-private partnerships used in the healthcare space; (2) purposes of and motivations of public-private partnerships in global public health; and (3) and facilitators, barriers, and challenges to date. CONCLUSIONS The literature review as well as the case studies analysis reveal that PPPs can represent a valid option for tackling global healthcare issues with a digital health approach. Further research is needed to complement the initial findings of the present paper, as well as to assess a wider pool of case studies and the different features that they might present.


  • Open Access

    Global return on investment and cost-effectiveness of WHO's HEAR interventions for hearing loss: a modelling study

    by David Tordrup, Robert Smith, Kaloyan Kamenov, Melanie Y Bertram, Nathan Green, Shelly Chadha


  • Open Access

    Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income

    by David Tordrup, Yvan Hutin, Karin Stenberg, Jeremy A. Lauer, David W. Hutton, Mehlika Toy, Nick Scott, Jagpreet Chhatwal, Andrew Ball


  • Open Access

    Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30

    by David Tordrup, Yvan Hutin, Karin Stenberg, Jeremy A Lauer, David W Hutton, Mehlika Toy, Nick Scott, Marc Bulterys, Andrew Ball, Gottfried Hirnschall


  • Open Access

    Evaluating medicine prices, availability and affordability in Bangladesh using World Health Organisation and Health Action International methodology

    by Lombe Kasonde, David Tordrup, Aliya Naheed, Wu Zeng, Shyfuddin Ahmed, Zaheer-Ud-Din Babar

    Previous studies have shown limited availability of medicines in health facilities in Bangladesh. While medicines are dispensed for free in public facilities, they are paid out-of-pocket in private pharmacies. Availability, price and affordability are key concerns for access to medicines in Bangladesh. The World Health Organization/Health Action International survey methodology was used to determine price, availability and affordability of 61 lowest price generic (LPG) and originator branded medicines in public facilities, private retail pharmacies and private clinics across 6 regions of Bangladesh. Medicines for non-communicable and infectious diseases, and both on and off the national Essential Medicines List were included. Prices were compared internationally using Median Price Ratio (MPR). Mean LPG (originator brand) availability in the public sector, private retail pharmacies, and private clinics was 37%, 63 (4) percent, and 54 (2) percent, respectively. Medicines for Non-Communicable Diseases (NCD) and essential medicines were significantly less available than infectious disease medicines and non-essential medicines, respectively. Mean LPG (originator brand) MPR was 0.977 in the public sector, 1.700 (3.698) in private retail pharmacies and 1.740 (3.758) in private clinics. Six medicines were expensive by international standards across all sectors. The least affordable treatments in both private sectors were bisoprolol (hypertension), metformin (diabetes) and atorvastatin (hypercholesterolemia). Availability and affordability of NCD medicines are key concerns where the burden of NCD is rising. These findings show improvement from earlier studies, but room for further advances in availability and affordability of NCD medicines in Bangladesh. A small number of medicines are consistently expensive across sectors in Bangladesh, suggesting the need for strategies to address prices for certain medicines.


  • Open Access

    PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION

    by David Tordrup, Christos Chouaid, Pim Cuijpers, William Dab, Johanna Maria van Dongen, Jaime Espin, Bengt Jönsson, Christian Léonard, David McDaid, Martin McKee, et al.

    Background:The importance of economic evaluation in decision making is growing with increasing budgetary pressures on health systems. Diverse economic evidence is available for a range of interventions across national contexts within Europe, but little attention has been given to identifying evidence gaps that, if filled, could contribute to more efficient allocation of resources. One objective of the Research Agenda for Health Economic Evaluation project is to determine the most important methodological evidence gaps for the ten highest burden conditions in the European Union (EU), and to suggest ways of filling these gaps.Methods:The highest burden conditions in the EU by Disability Adjusted Life Years were determined using the Global Burden of Disease study. Clinical interventions were identified for each condition based on published guidelines, and economic evaluations indexed in MEDLINE were mapped to each intervention. A panel of public health and health economics experts discussed the evidence during a workshop and identified evidence gaps.Results:The literature analysis contributed to identifying cross-cutting methodological and technical issues, which were considered by the expert panel to derive methodological research priorities.Conclusions:The panel suggests a research agenda for health economics which incorporates the use of real-world evidence in the assessment of new and existing interventions; increased understanding of cost-effectiveness according to patient characteristics beyond the “-omics” approach to inform both investment and disinvestment decisions; methods for assessment of complex interventions; improved cross-talk between economic evaluations from health and other sectors; early health technology assessment; and standardized, transferable approaches to economic modeling.